Patents

Sandoz v. Amgen: The Patent Dance Is a Choice, Not a Command

The Supreme Court's first reading of the biosimilars statute held that the BPCIA's elaborate pre-litigation information exchange cannot be forced by federal injunction, and that a biosimilar applicant may give its marketing notice before the FDA licenses the product.

February 10, 2025
Vials of a biologic medicine on a laboratory bench
The biosimilars statute built an elaborate choreography of disclosure; the Court decided how much of it is actually enforceable. Shutterstock
Educational content, not legal advice. This article explains general legal concepts. It does not create an attorney–client relationship. For your specific situation, consult a licensed attorney.

Sandoz Inc. v. Amgen Inc., 582 U.S. 1 (2017), No. 15-1039 (consolidated with Amgen’s cross-petition, No. 15-1195), was decided on June 12, 2017. Justice Thomas wrote for a unanimous Court. It was the Supreme Court’s first encounter with the Biologics Price Competition and Innovation Act of 2009 (BPCIA), the statute that created an abbreviated pathway for “biosimilar” copies of biologic medicines — and with the intricate pre-litigation procedure that practitioners had already nicknamed the “patent dance.” The decision answered two narrow but structurally important questions about how that dance is enforced, and in doing so it reset the leverage between innovator biologics companies and the biosimilar applicants seeking to follow them to market.

At a glance

  • Case: Sandoz Inc. v. Amgen Inc., 582 U.S. 1 (2017), Nos. 15-1039 & 15-1195
  • Court: Supreme Court of the United States, on review of the Federal Circuit
  • Decided: June 12, 2017; unanimous opinion by Justice Thomas (Justice Breyer filed a brief concurrence)
  • Holdings: (1) The BPCIA’s information-exchange step is not enforceable by injunction under federal law; the statute’s own artificial-infringement remedy is the consequence of skipping it. (2) A biosimilar applicant may give its 180-day notice of commercial marketing before, not only after, the FDA licenses the product. (3) Whether the dance can be compelled by state law (here, California unfair-competition law) was left open and remanded.

The architecture of the patent dance

A biologic is a large, complex molecule manufactured in living cells — not the small, fully characterized chemical of a conventional pill. Congress could not simply graft the Hatch-Waxman generic-drug scheme onto biologics, so the BPCIA invented its own choreography. Once the FDA accepts a biosimilar application (an “aBLA”) referencing an approved biologic, the statute lays out a sequence of steps codified at 42 U.S.C. § 262(l). The applicant “shall” provide the reference-product sponsor with a copy of its application and manufacturing information within 20 days. The parties then trade lists of patents, exchange contentions on validity and infringement, and negotiate which patents go into a first wave of litigation. Separately, § 262(l)(8)(A) requires the applicant to give the sponsor notice “not later than 180 days before the date of the first commercial marketing” of the biosimilar.

Amgen markets filgrastim as Neupogen. Sandoz sought to market a biosimilar, Zarxio, but declined to hand over its application and manufacturing information under § 262(l)(2)(A), and gave its marketing notice before the FDA had licensed Zarxio. Amgen sued, arguing that the disclosure step was mandatory and injunctable, and that a valid 180-day notice could only be given after licensure — which would push any biosimilar launch six months past approval. The Federal Circuit gave each side a partial win. The Supreme Court took both questions.

Holding one: the disclosure step has its own remedy

The Court held that the information-exchange requirement of § 262(l)(2)(A) is not enforceable by a federal injunction. The reasoning is a study in reading a statute as an integrated machine rather than a list of commands. Congress, the Court observed, did not leave the consequence of non-disclosure to judicial improvisation; it specified one. If an applicant fails to turn over its application and manufacturing information, § 271(e)(2)(C)(ii) of the Patent Act and § 262(l)(9)(C) of the BPCIA together authorize the sponsor — and only the sponsor — to bring an immediate declaratory-judgment action for “artificial” patent infringement on any patent it believes is at issue.

That remedy, the Court reasoned, is the point. By skipping disclosure, the applicant forfeits its ability to control the shape and timing of the litigation and hands the sponsor the keys to a declaratory-judgment suit on the sponsor’s own terms. Because Congress supplied a tailored consequence, courts may not layer an injunction on top of it. The “shall” in § 262(l)(2)(A) is real, but its enforcement runs through the statute’s own gearing, not through the equity powers of a district court.

Holding two: notice can precede licensure

On the second question the Court was, if anything, more direct. Section 262(l)(8)(A) requires notice 180 days before first commercial marketing. Amgen wanted to read into it a second timing rule — that the notice is effective only if given after the FDA licenses the product. The text supplies no such requirement. The only event the statute ties the notice to is commercial marketing, which necessarily presupposes an already-licensed product; the license is the precondition for marketing, not a precondition for the notice. An applicant may therefore give effective notice while its application is still pending. The practical effect is significant: a biosimilar need not wait an extra half-year after approval to launch, because the 180-day clock can already have run by licensure.

The state-law question left dangling

The Court declined to resolve whether Amgen could compel the disclosure step through California’s unfair-competition law, an avenue the Federal Circuit had not fully addressed. It remanded for the lower court to decide two antecedent issues: whether the BPCIA preempts such a state-law claim, and whether Sandoz’s conduct was even “unlawful” under California law given the federal scheme. That remand kept alive a meaningful question about whether innovators retain any coercive tool to force disclosure — a question the opinion deliberately did not answer.

Open questions

The opinion settled federal enforcement of the dance but left the surrounding terrain unsettled. The preemption question remanded to the Federal Circuit invites continued litigation over whether state law can do what federal injunctions cannot. The decision also says nothing about the strategic calculus it sets in motion: an applicant who skips disclosure trades procedural control for speed, but the value of that trade depends on how aggressively sponsors actually wield the declaratory-judgment remedy. And because the patent dance is voluntary in the sense the Court described, the body of district-court practice that has grown up around § 262(l) now operates against a backdrop where either party may decline to play — reshaping settlement leverage in ways the statute’s drafters may not have anticipated.

Implications

  • The dance is optional, but not free. A biosimilar applicant may decline to exchange information, but it surrenders control over which patents are litigated and when, and exposes itself to a sponsor-initiated declaratory-judgment suit.
  • Launch timing moved up. Because the 180-day marketing notice can be given before licensure, biosimilars can reach the market sooner after approval — a direct competitive and pricing consequence.
  • Read remedies before reading “shall.” The decision is a reminder that a statutory “shall” means little without identifying the consequence Congress attached; here the consequence, not an injunction, defines the obligation.
  • State law remains a live front. Innovators continue to probe whether unfair-competition and similar state theories can compel disclosure, an issue the Court expressly left open.

Frequently asked questions

What is the “patent dance”? It is the colloquial name for the BPCIA’s pre-litigation procedure under 42 U.S.C. § 262(l), in which a biosimilar applicant and the reference-product sponsor exchange the application, manufacturing details, and patent contentions and then stage patent litigation in waves.

Did the Court make the dance mandatory or optional? Functionally optional under federal law. The applicant can decline to disclose, but the statute’s own remedy — an immediate declaratory-judgment action available to the sponsor — is the consequence, and no federal injunction can force the exchange.

Why does the 180-day notice timing matter so much? If notice could only be effective after FDA licensure, every biosimilar launch would be delayed roughly six months past approval. By allowing pre-licensure notice, the Court let the clock run during the application period, accelerating market entry.

Authorities and sources